Update on nitrosamine impurities
Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral...
Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral...
Brussels – Carcinogenic titanium dioxide, the EU Court annuls the Community regulation. The European Commission has based its assessments on...
Bio chem Srl informs you that from 2 January 2023 it has been authorized by the Istituto Poligrafico e Zecca dello Stato to publish data in the...
On June 18, 2020, the EU Regulation 878/2020 was published, which amends Annex II of the REACH Regulation on Safety Data Sheets. This new regulation...
The GMP Medicines Inspections and Authorizations Office, in confirming the prescriptions already disclosed with the communication of 13 July 2022,...
The launch of an administrative procedure aimed at verifying the existence of the conditions for maintaining the validity of the marketing...
The decrees on medical devices govern aspects of national competence in continuity with the legislative decrees 46/97, 507/92 and 332/2000,...
Companies holding marketing authorization for non-steroidal anti-inflammatory drugs (NSAIDs) for systemic use, both as monocomponents and in...
From 9 June 2022 the portal for the "vigormacious" online reporting is no longer active.From 9 June to 20 June 2022, the start date of the new online...